Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
AbCellera (Nasdaq: ABCL) has announced a multi-year partnership with Versant Ventures to discover therapeutic antibodies for various targets. This collaboration builds on previous successful partnerships, enabling three stealth-stage companies under Versant. AbCellera will receive research payments and potential milestone payments, along with royalties on product sales. The partnership aims to enhance the capabilities of small biotech firms, improving their efficiency in developing antibody therapeutics.
- Multi-year collaboration with Versant Ventures to discover therapeutic antibodies.
- AbCellera receives research payments and has the potential for milestone payments and royalties.
- Partnership aims to empower smaller biotech companies to accelerate drug development.
- None.
Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive research payments from the companies and will be eligible to receive downstream clinical and commercial milestone payments plus royalties on net sales of products. Further terms are not disclosed.
"In recent years we have made a series of investments into the next generation of therapeutic antibodies,” said
“AbCellera’s discovery technology provides a complete solution for antibody therapeutics that unlocks new opportunities and levels the playing field for smaller companies, allowing them to advance programs faster, more efficiently and with a competitive advantage,” said
Previously, Versant and AbCellera partnered in separate multi-target deals to enable three of the firm’s stealth-stage companies with new approaches to optimize and expand antibody therapies. These include antibody-focused newcos in the fields of immunology and oncology based in
About
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Versant Legal Notices
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220722005487/en/
AbCellera
Media:
Business Development:
Investor Relations:
Versant
Source:
FAQ
What is the new collaboration between AbCellera and Versant Ventures about?
What benefits does AbCellera expect from its partnership with Versant Ventures?
How many companies are involved in AbCellera's collaboration with Versant Ventures?